Abstract
Ureteroscopy is a commonly performed procedure, with post operative pain that can lead to re-visits and opioid prescribing. Perioperative gabapentinoids have shown promise in decreasing pain and opioid use. We hypothesized that single dose perioperative pregabalin would be safe and efficacious for decreasing pain after ureteroscopy. This was an IRB approved and registered blinded, placebo-controlled trial conducted at a single institution. Patients undergoing ureteroscopy without histories that would limit use of opioids, gabapentinoids, and non-steroidal medications were enrolled. Either 300mg pregabalin or placebo was administered 1 hour before ureteroscopy. Pain was assessed using a visual analogue before administration and 1 hour after surgery. Clinical factors, pain scores, a proxy for cognition, patient satisfaction, and opioid prescribing were assessed in the first 30 post operative days. 118 patients were enrolled over a 2-year period. Patients who received pregabalin were younger than those who received placebo (median of 44 years vs 57). Post operative pain scores were higher in those who received pregabalin (3.7 vs 2.0, P = .004), a finding that remained statistically significant when accounting for patient age and preoperative pain scores. There was no difference in the measure of cognition or in reports of adverse events. In this trial evaluating the efficacy of a single dose perioperative pregabalin in ureteroscopy, pregabalin did not decrease postoperative pain when compared to placebo. Urologists should not routinely use this adjunctive medication in ureteroscopy, as it is unlikely to provide benefit.

This publication has 27 references indexed in Scilit: